Form 4: Adaptive Bio CCO Sells Shares After Option Exercise
Insider Transaction Report
Adaptive Biotechnologies' Chief Commercial Officer, Sharon Benzeno, exercised stock options and subsequently sold a significant number of shares under a pre-arranged 10b5-1 trading plan.
Summary
- Sharon Benzeno, Chief Commercial Officer of Adaptive Biotechnologies Corp (ADPT), engaged in multiple transactions on November 20 and 21, 2025.
- All reported transactions were executed pursuant to a Rule 10b5-1 trading plan adopted by Benzeno on August 18, 2025.
- Benzeno acquired a total of 510,470 shares of common stock through the exercise of stock options at prices ranging from $3.99 to $12.14 per share.
- Concurrently, Benzeno disposed of a total of 606,402 shares of common stock through sales at weighted average prices of $16.54 and $16.91 per share.
- Following these reported transactions, Benzeno's direct beneficial ownership of Adaptive Biotechnologies common stock is 296,791 shares.
Sentiment
Score: 4
Explanation: While the transactions were pre-planned under a 10b5-1 plan, the net reduction in insider ownership through significant sales can be interpreted as a moderately negative signal regarding management's long-term conviction or a desire for liquidity at current price levels.
Positives
- Transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating planned liquidity management rather than a reaction to new, undisclosed information.
- The exercise of options at lower prices and subsequent sale at higher market prices demonstrates a profitable realization of equity compensation.
Negatives
- A net reduction in the Chief Commercial Officer's direct beneficial ownership of common stock, as total shares sold exceeded shares acquired through option exercises by 95,932 shares.
- Significant insider selling, even if pre-planned, can sometimes be perceived negatively by the market.
Risks
- Potential negative market perception due to significant insider selling, which could put downward pressure on the stock price.
- Reduced alignment of the Chief Commercial Officer's personal equity holdings with long-term shareholder interests due to the net decrease in ownership.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: May view the net insider selling as a signal of reduced confidence or a desire for liquidity by a key executive, potentially leading to negative sentiment or downward pressure on the stock price.
Key Dates
| Date | Description |
|---|---|
| 04/19/2018 | Vesting start date for certain stock options (1/4 of shares). |
| 11/01/2018 | Vesting start date for certain stock options (1/4 of shares). |
| 10/01/2019 | Vesting start date for certain stock options (1/4 of shares). |
| 01/01/2020 | Vesting start date for certain stock options (1/4 of shares). |
| 03/04/2023 | Vesting start date for certain stock options (1/4 of shares). |
| 03/06/2024 | Vesting start date for certain stock options (1/4 of shares). |
| 03/04/2025 | Vesting start date for certain stock options (1/4 of shares). |
| 08/18/2025 | Date Rule 10b5-1 trading plan was adopted by the reporting person. |
| 11/20/2025 | Transaction date for multiple option exercises and share sales. |
| 11/21/2025 | Transaction date for multiple option exercises and share sales. |
| 11/24/2025 | Signature date of the Form 4 filing. |
| 04/25/2027 | Expiration date for certain stock options. |
| 02/07/2028 | Expiration date for certain stock options. |
| 10/01/2028 | Expiration date for certain stock options. |
| 02/07/2029 | Expiration date for certain stock options. |
| 03/04/2032 | Expiration date for certain stock options. |
| 03/06/2033 | Expiration date for certain stock options. |
| 03/04/2034 | Expiration date for certain stock options. |
Recommendation
holdThe filing indicates significant insider selling by a key executive, Sharon Benzeno, who exercised options and then sold a larger number of shares. While these transactions were conducted under a pre-arranged 10b5-1 plan, mitigating the immediate negative signal of opportunistic selling, the net reduction in insider ownership suggests a desire for liquidity at current price levels. This action, by itself, does not provide a strong 'buy' signal, nor does it indicate fundamental deterioration warranting a 'sell' given the pre-planned nature. Therefore, a 'hold' recommendation is appropriate, advising investors to monitor future insider activity and company fundamentals for clearer directional signals.
Keywords
Adaptive Biotechnologies, ADPT, Form 4, Insider Trading, Stock Options, Share Sale, 10b5-1 Plan, Sharon Benzeno, Chief Commercial Officer, Equity Compensation
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.